Means and methods for detecting charcot-leyden crystals
Sequence-optimized VHH antibodies conjugated with radionuclide tracers effectively bind to crystalline galectin-10, addressing the challenge of imaging Charcot-Leyden crystals for therapeutic monitoring and patient selection.
Patent Information
- Application Number
- PCT/EP2026/062898
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2025-05-05
- Filing Date
- 2026-05-05
- Publication Date
- 2026-11-12
AI Technical Summary
Current detection methods for Charcot-Leyden crystals (CLCs) are inadequate for efficient imaging and monitoring in patients with conditions such as allergic asthma and cancer, particularly due to the need for a small format PET tracer that can penetrate mucus plugs and maintain stability during therapy.
Development of sequence-optimized VHH antibodies that specifically bind to crystalline galectin-10, conjugated with radionuclide tracers and bifunctional chelators, allowing for effective PET imaging of CLCs by maintaining stability and providing clear imaging windows.
The optimized VHH antibodies provide enhanced biophysical properties, enabling efficient in vivo binding and imaging of CLCs, facilitating therapeutic monitoring and patient selection.
Smart Images

Figure IMGF000033_0001 
Figure IMGF000033_0002 
Figure IMGF000019_0001_TABLE
Abstract
Description
[0001] BaLa / PETTRACER / 880
[0002] MEANS AND METHODS FOR DETECTING CHARCOT-LEYDEN CRYSTALS
[0003] Field of the invention
[0004] The present disclosure generally relates to antibody conjugates, to methods for imaging antibody conjugates in vivo, and methods and compositions relating to antibody conjugates. The present disclosure specifically relates to antibody conjugates which specifically recognize the crystalline form of galectin 10 and to methods for imaging galectin 10 antibody conjugates in vivo.
[0005] Introduction to the invention
[0006] Charcot-Leyden crystals (CLCs) were first described in 1853 and are microscopic, colourless crystals found in patients with certain conditions including allergic asthma and parasitic infections. CLCs are frequently observed in human tissues and secretions associated with an eosinophilic inflammatory response. In addition to asthma and parasitic infections, these crystals have been found in patients with cancer, for example myeloid leukemia. Structurally, CLCs accumulate as extracellular hexagonal bipyramidal crystals with a length of 20-40 pm and a width of 2-4 pm. The protein forming these crystals has been identified as galectin-10.
[0007] Galectin-10 (also known as Charcot Leyden Crystal Protein) is a small (16.5kDa), hydrophobic, glycan-binding protein expressed abundantly in the bone marrow, primarily by eosinophils (Chua et al. (2012) PLoS One. 7(8): e42549). Galectin-10 is also produced to a lesser extent by basophils and Foxp3-positive Tregs (Kubach et al. (2007) Blood 110(5): 1550-8). This protein is among the most abundant of eosinophil constituents, representing 7%-10% of total cellular protein. Galectin-10 (herein abbreviated as Gal 10) is only found in humans, it lacks a secretion peptide signal and transmembrane domain, and is secreted under certain conditions by non-classical and novel apocrine mechanisms.
[0008] It would be desirable to generate a detection agent such as a PET tracer as a helpful diagnostic agent for detection and monitoring of the CLC presence embedded in mucus plugs in the lungs, and support patient selection during clinical development. For such a PET tracer a small format is desired for efficient penetration of mucus plugs. VHHs as modality are well-suited for use in PET imaging, as they have a short serum half-life that is beneficial for fast clearance from the circulation after systemic administration, to achieve a good window between tissue and blood. Ideally, a PET tracer would be a crystalline Gal10 binding agent that is not dissoluting the CLCs, so that it can be used for monitoring CLC presence during the course of therapy, as readout for therapeutic efficacy. In the published application WO2019197675 several VHH binders targeting crystalline galectin 10 are described. In the present application three VHHs were selected for generating sequence variants with improved biophysical characteristics: i) 13C03 depicted as SEQ ID NO: 263 in WO2019197675, herein depicted as SEQ ID NO: 1), ii) 15A02 depicted asBaLa / PETTRACER / 880
[0009] SEQ ID NO: 266 in WO2019197675, herein depicted as SEQ ID NO: 2 and iii) 13C06 depicted as SEQ ID NO: 253 in WO2019197675, herein depicted as SEQ ID NO: 3.
[0010] Summary of the invention
[0011] The instant invention provides sequence optimized variants for two different VHH antibodies specifically targeting crystalline galectin-10. These sequence variants have improved biophysical properties with respect to the original VHH antibodies.
[0012] Thus in a first aspect the invention provides an immunoglobulin variable domain (IVD) that specifically binds to galectin 10, such as the crystalline form of galectin 10, said IVD comprises a CDR3 sequence consisting of an amino acid sequence with maximally two amino acids different from SEQ ID No. 25 or 28 and / or wherein said IVD comprises a CDR2 sequence consisting of an amino acid sequence with maximally two amino acids different from SEQ ID No.
[0013] 24 or 27 and / or wherein said IVD comprises a CDR1 sequence consisting of an amino acid sequence maximally two amino acids different from SEQ ID no. 23 or 26.
[0014] In a second aspect in the IVD as described herein above the CDR3 sequence is as depicted in SEQ ID No. 25 or 28 and / or wherein the CDR2 sequence is depicted in SEQ ID No. 24 or 27 and / or wherein the CDR1 sequence is depicted in SEQ ID No. 23 or 26.
[0015] In another aspect the IVD comprises an amino acid sequence with at least 90% identity over the full length of SEQ ID No. 17 or SEQ ID No. 22.
[0016] In a specific aspect the IVD as described herein before is an immunoglobulin single variable domain (ISVD).
[0017] In another specific aspect the immunoglobulin single variable domain (ISVD) is derived from camelids.
[0018] In another aspect the immunoglobulin single variable domain (ISVD) comprises an amino acid sequence depicted in the sequences SEQ ID No. 17 or 22.
[0019] In another aspect the invention provides a labelled-lVD conjugate comprising:
[0020] a. an IVD as described herein before and
[0021] b. a detection label conjugated to the IVD, wherein the detection label is a radionuclide tracer, a fluorophore or a nanoparticle.
[0022] In another aspect the labelled-lVD conjugate as described herein the radionuclide tracer is conjugated to the IVD with a bifunctional chelator, prosthetic group, or linker, and wherein the bifunctional chelator, prosthetic group, or linker is attached to the IVD and to the radionuclide tracer.
[0023] In another aspect in the labelled-lVD conjugate the bifunctional chelator comprises a chelator selected from desferrioxamine (DFO*NCS), 1,4,7-Triazacyclononane (TACN); 1,4,7,10-Tetraazacyclododecane (Cyclen); 1,4,7,10-Tetraazacyclododecane-1,7-diacetic acid (D02A); 1,4,7,10-Tetraazacyclododecane-1,4,7-triacetic acid trisodium salt (D03A); 1,4,7,10-BaLa / PETTRACER / 880
[0024] Tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA); 1, 4,7,10-Tetraazacyclododecane- 1.4.7.10-tetra(methylene phosphonic acid) (DOTP); 1,4, 8, 11-Tetraazacyclotetradecane-1, 4, 8, ll-tetraacetic acid (TETA); 2,2',2”,2”’-(l,4,8,ll-tetraazacyclotetradecane-1,4,8,1 1-tetrayl)tetraacetamide (TETAM); 1,4,7,10-Tetrakis(carbamoylmethyl)-1,4,7,10-tetraazacyclododecane (DOTAM); 2,2',2”-(1,4,7,10-tetraazacyclododecane-1,4,7-triyl)triacetamide (D03AM); 1 ,8-Diamino-3,6, 10, 13, 16, 19-hexaazabicyclo[6,6,6]-eicosane (DiAmSar); 1,4, 8,1 1-Tetraazabicyclo[6.6.2]hexadecane (CB-Cyclam); 2,2'-(1,4,8, 1 1-tetraazabicyclo[6.6.2]hexadecane-4,1 1 -diyl)diacetic acid (CB-TE2A); 1,4,7-Triazacyclononane-1,4,7-triacetic acid (NOTA); 1,4,7-Triazacyclononane- 1,4,7 -tri(methylene phosphonic acid) (NOTP); 3-(((4,7-bis((hydroxy(hydroxymethyl)phosphoryl)methyl)-1,4,7-triazonan-l-yl)methyl)(hydroxy)phosphoryl)propanoic acid (NOPO); 2,2',2”-(1,4,7-triazacyclononane-1,4,7-triyl)triacetamide (NOTAM) ; 2, 2', 2”, 2”’ - ((((carboxymethyl)azanediyl)bis(ethane-2,l-diyl))bis(azanetriyl))tetraacetic acid (DTPA); 3,6,9, 15-Tetraazabicyclo[9.3.1]pentadeca-l(15),11,13-triene-3,6,9-triacetic acid (PCTA); 2,2',2”,2”’-(1,4,7,10-tetraazacyclotridecane- 1.4.7.10-tetrayl)tetraacetic acid (TRITA); 2,2',2”,2”’-(1,4,7,10-tetraazacyclotridecane-1,4,7,10-tetrayl)tetraacetamide (TRITAM); 2,2',2”-(1,4,7,10-tetraazacyclotridecane-1,4,7-triyl)triacetamide (TRITRAM); and 3,3',3”-(((1,4,7-triazonane-1,4,7-triyl)tris(methylene))tris(hydroxyphosphoryl))tripropanoic acid (TRAP); or a combination of any two or more thereof.
[0025] In another aspect in the labelled-lVD conjugate the radionuclide tracer is selected from11C,13N,150,18F,44Sc,45Ti,52Mn,64Cu,68Ga,44Sc,76Br,82Rb,86Y,89Zr,90Y,99mTc,111In,124l,1311,43K,52Fe,57Co,67Cu,67Ga,77Br,81Rb,81mKr,87mSr,89Zr,113mln,123l,125l,127Cs,129Cs,132l,177Lu ,186Re,197Hg,203Pb.206Bi,82Sr,188Re,60Cu,61Cu,62Cu,225Ac,225Ra, and a combination of any two or more thereof.
[0026] In another aspect the invention provides a nucleic acid molecule encoding the IVD as described herein before.
[0027] In another aspect the invention provides a vector comprising the nucleic acid molecule as described herein before.
[0028] In another aspect the invention provides a host cell comprising the nucleic acid molecule as described herein or the vector comprising the nucleic acid as described herein.
[0029] Figures
[0030] Figure 1: Different capacity in CLC dissolution of Gal10 VHHs. The abbreviations in the Figure correspond with these from Table 1.
[0031] Figure 2: ITC of VHH antibody 13C03. VHH antibody 13C03 binds well to both forms of Gal10, with an eguilibrium dissociation constant KD of 1.7 nM for His-Gal10, and a KD of 11 nM to Gal10BaLa / PETTRACER / 880
[0032] without tags. The stoichiometry of the complex is in both cases 1:2, binding of 2 VHHs to one Gal10 dimer. This molar ratio was confirmed by analysis of the ITC complexes on SDS-PAGE.
[0033] Figure 3: Crystal structure of Gal 10 VHHs 13C03 and 15A02, binding to distinct epitopes on Gal10. Cartoon representations for the determined Gal10:VHH-15A02 and Gal10-Y69E:VHH-13C03 crystal structures with Galectin-10 coloured in light grey, and VHHs in black.
[0034] Figure 4: seguence alignment of VHH 13C03, VHH 13C06 and VHH 15A02. IMGT CDR1, 2 & 3 regions are shaded in light grey. VHH hallmark residues are highlighted in dark grey. Dots denote amino acid residues identical to reference seguence. CDR-based potential post-translational modification motifs are in bold and underlined.
[0035] Figure 5: Melting temperature (Tm) plots and derivative plot of seguence optimized variants of Gal10 VHHs 13C03, 13C06, and 15A02, respectively. Results depict averages of 2 replicates.
[0036] Figure 6: In vitro autoradiography of89Zr-DFO*- P01900033 and89Zr-DFO*- P01900038. It is observed that both [89Zr]Zr-DFO*-P01900033 and [89Zr]Zr-DFO*-P01900038 specifically bind to CLCs present in mouse lungs slices. [89Zr]Zr-DFO-P01900033 seems to show higher uptake than [89Zr]Zr-DFO-P01900038.
[0037] Figure 7: Results of the ex vivo biodistribution at endpoint (2 hours). Uptake of radiotracer in tissues is depicted as % injected dose per gram tissue, and as Standardized Uptake Value (SUV): ((SUV; tissue activity concentration (MBg / g) / [injected activity (MBg) / body weight (g)])).
[0038] Figure 8: In vivo pPET-CT data. In panel 8A, the maximum intensity projection PET images of all 4 mice per group at timepoint 110-120 minutes are depicted, in figure 8B detailed picture on 1 mouse from each group.
[0039] Figure 9: Lung retention. It is shown that a wwidespread uptake and retention in the lungs is present. Time activity curves of lungs (Standardized Uptake Values (SUV, g / mL)) 0-120 minutes of [89Zr]Zr-DFO-P01900033 (n=2) and [89Zr]Zr-DFO-P01900038 (n=4). Scan was started 3-7 min p.i..
[0040] Figure 10: Ex vivo autoradiography was done on lung slices from all animals injected with [89Zr]Zr-DFO-P01900033 indicating a punctuate staining for both groups. The data show that the radioconjugate of P01900033 binds well to Gal10-containing CLCs in vivo following intravenous injection.
[0041] Figure 11: Ex vivo autoradiography was done on lung slices from all animals injected with [89Zr]Zr-DFO-P01900038 indicating a punctuate staining for both groups. The data show that the radioconjugate of P01900038 binds well to Gal10-containing CLCs in vivo following intravenous injection.BaLa / PETTRACER / 880
[0042] Detailed description of the invention
[0043] The present invention will be described with respect to particular embodiments and with reference to certain drawings but the invention is not limited thereto but only by the claims. Any reference signs in the claims shall not be construed as limiting the scope. The drawings described are only schematic and are non-limiting. In the drawings, the size of some of the elements may be exaggerated and not drawn on scale for illustrative purposes. Where the term "comprising" is used in the present description and claims, it does not exclude other elements or steps. Where an indefinite or definite article is used when referring to a singular noun e.g. "a" or "an", "the", this includes a plural of that noun unless something else is specifically stated. Furthermore, the terms first, second, third and the like in the description and in the claims, are used for distinguishing between similar elements and not necessarily for describing a sequential or chronological order. It is to be understood that the terms so used are interchangeable under appropriate circumstances and that the embodiments of the invention described herein are capable of operation in other sequences than described or illustrated herein.
[0044] The following terms or definitions are provided solely to aid in the understanding of the invention. Unless specifically defined herein, all terms used herein have the same meaning as they would to one skilled in the art of the present invention. Practitioners are particularly directed to Sambrook et al., Molecular Cloning: A Laboratory Manual, 4th ed., Cold Spring Harbor Press, Plainsview, New York (2012); and Ausubel et al., Current Protocols in Molecular Biology (Supplement 114), John Wiley & Sons, New York (2016), for definitions and terms of the art. The definitions provided herein should not be construed to have a scope less than understood by a person of ordinary skill in the art.
[0045] As used herein, the term "nucleotide sequence" refers to a polymeric form of nucleotides of any length, either deoxyribonucleotides or ribonucleotides, or analogs thereof. Nucleotide sequences may have any three-dimensional structure, and may perform any function, known or unknown. Non-limiting examples of nucleotide sequences include a gene, a gene fragment, exons, introns, messenger RNA (mRNA), transfer RNA, ribosomal RNA, ribozymes, cDNA, recombinant polynucleotides, branched polynucleotides, plasmids, vectors, isolated DNA of any sequence, control regions, isolated RNA of any sequence, nucleic acid probes, and primers. The nucleotide sequence may be linear or circular.
[0046] As used herein, the term "polypeptide" refers to a polymeric form of amino acids of any length, which can include coded and non-coded amino acids, chemically or biochemically modified or derivatized amino acids, and polypeptides having modified peptide backbones. Polypeptide sequences can be depicted with the single-letter (or one letter) amino acid code or the three letter amino acid code as depicted here below:BaLa / PETTRACER / 880
[0047] Amino acid Three leter code One leter code
[0048] alanine ala A
[0049] arginine arg R
[0050] asparagine asn N
[0051] aspartic acid asp D
[0052] asparagine or aspartic acid asx B
[0053] cysteine cys C
[0054] glutamic acid glu E
[0055] glutamine gin Q
[0056] glutamine or glutamic acid gl:x Z
[0057] glycine gly G
[0058] histidine his H
[0059] isoleucine ile I
[0060] leucine leu L
[0061] lysine lys K
[0062] methionine met M
[0063] phenylalanine phe F
[0064] proline pro P
[0065] serine ser S
[0066] threonine th r T
[0067] tiyptophan tip A'
[0068] tyrosine tyr Y
[0069] valine val V
[0070]
[0071] The term “immunoglobulin domain” as used herein refers to a globular region of an antibody chain (such as e.g., a chain of a conventional 4-chain antibody or of a heavy chain antibody), or to a polypeptide that essentially consists of such a globular region. Immunoglobulin domains are characterized in that they retain the immunoglobulin fold characteristic of antibody molecules, which consists of a two-layer sandwich of about seven antiparallel beta-strands arranged in two beta-sheets, optionally stabilized by a conserved disulphide bond.
[0072] The term “immunoglobulin variable domain” as used herein means an immunoglobulin domain essentially consisting of four “framework regions” which are referred to in the art and herein below as “framework region 1” or “FR1”; as “framework region 2” or “FR2”; as “framework region 3” or “FR3”; and as “framework region 4” or “FR4”, respectively; which framework regions are interrupted by three “complementarity determining regions” or “CDRs”, which are referred to in the art and herein below as “complementarity determining region 1” or “CDR1”; as “complementarity determining region 2” or“CDR2”; and as “complementarity determining region 3” or “CDR3”, respectively. Thus, the general structure or sequence of an immunoglobulin variable domain can be indicated as follows: FR1 - CDR1 - FR2 - CDR2 - FR3 - CDR3 - FR4. It is the immunoglobulin variable domain(s) that confer specificity to an antibody for the antigen by carrying the antigen-binding site.BaLa / PETTRACER / 880
[0073] The term “immunoglobulin single variable domain” (abbreviated as "ISVD"), equivalent to the term “single variable domain”, defines molecules wherein the antigen binding site is present on, and formed by, a single immunoglobulin domain. This sets immunoglobulin single variable domains apart from “conventional” immunoglobulins or their fragments, wherein two immunoglobulin domains, in particular two variable domains, interact to form an antigen binding site. Typically, in conventional immunoglobulins, a heavy chain variable domain (VH) and a light chain variable domain (VL) interact to form an antigen binding site. In this case, the complementarity determining regions (CDRs) of both VH and VL will contribute to the antigen binding site, i.e. a total of 6 CDRs will be involved in antigen binding site formation.
[0074] In view of the above definition, the antigen-binding domain of a conventional 4-chain antibody (such as an IgG, IgM, IgA, IgD or IgE molecule; known in the art) or of a Fab fragment, a F(ab')2 fragment, an Fv fragment such as a disulphide linked Fv or a scFv fragment, or a diabody (all known in the art) derived from such conventional 4-chain antibody, would normally not be regarded as an immunoglobulin single variable domain, as, in these cases, binding to the respective epitope of an antigen would normally not occur by one (single) immunoglobulin domain but by a pair of (associated) immunoglobulin domains such as light and heavy chain variable domains, i.e., by a VH-VL pair of immunoglobulin domains, which jointly bind to an epitope of the respective antigen.
[0075] In contrast, immunoglobulin single variable domains are capable of specifically binding to an epitope of the antigen without pairing with an additional immunoglobulin variable domain. The binding site of an immunoglobulin single variable domain is formed by a single VH / VHH or VL domain. Hence, the antigen binding site of an immunoglobulin single variable domain is formed by no more than three CDRs.
[0076] As such, the single variable domain may be a light chain variable domain sequence {e.g., a VL-sequence) or a suitable fragment thereof; or a heavy chain variable domain sequence {e.g., a VH-sequence or VHH sequence) or a suitable fragment thereof; as long as it is capable of forming a single antigen binding unit i.e., a functional antigen binding unit that essentially consists of the single variable domain, such that the single antigen binding domain does not need to interact with another variable domain to form a functional antigen binding unit).
[0077] In one embodiment of the invention, the immunoglobulin single variable domains are heavy chain variable domain sequences {e.g., a VH-sequence); more specifically, the immunoglobulin single variable domains can be heavy chain variable domain sequences that are derived from a conventional four-chain antibody or heavy chain variable domain sequences that are derived from a heavy chain antibody.
[0078] For example, the immunoglobulin single variable domain may be a (single) domain antibody (or an amino acid sequence that is suitable for use as a (single) domain antibody), a "dAb" or dAb (or an amino acid sequence that is suitable for use as a dAb) or a Nanobody (as defined herein,BaLa / PETTRACER / 880
[0079] and including but not limited to a VHH); other single variable domains, or any suitable fragment of any one thereof.
[0080] In particular, the immunoglobulin single variable domain may be a Nanobody® (as defined herein) or a suitable fragment thereof. [Note: Nanobody®, Nanobodies® and Nanoclone® are registered trademarks of Ablynx N.V.] For a general description of Nanobodies, reference is made to the further description below, as well as to the prior art cited herein, such as e.g. described in WO 08 / 020079 (page 16). A Nanobody® is equivalent to the term VHH or VHH antibody.
[0081] “VHH domains”, also known as VHHs, VHH domains, VHH antibody fragments, and VHH antibodies, have originally been described as the antigen binding immunoglobulin (variable) domain of “heavy chain antibodies” ( / .e., of “antibodies devoid of light chains”; Hamers-Casterman et al (1993) Nature 363: 446-448). The term “VHH domain” has been chosen in order to distinguish these variable domains from the heavy chain variable domains that are present in conventional 4-chain antibodies (which are referred to herein as “VH domains” or “VH domains”) and from the light chain variable domains that are present in conventional 4-chain antibodies (which are referred to herein as “VL domains” or “VL domains”). For a further description of VHHs and Nanobodies, reference is made to the review article by Muyldermans (Reviews in Molecular Biotechnology 74: 277-302, 2001), as well as to the following patent applications, which are mentioned as general background art: WO 94 / 04678, WO 95 / 04079 and WO 96 / 34103 of the Vrije Universiteit Brussel; WO 94 / 25591, WO 99 / 37681, WO 00 / 40968, WO 00 / 43507, WO 00 / 65057, WO 01 / 40310, WO 01 / 44301, EP 1134231 and WO 02 / 48193 of Unilever; WO 97 / 49805, WO 01 / 21817, WO 03 / 035694, WO 03 / 054016 and WO 03 / 055527 of the Vlaams Instituut voor Biotechnologie (VIB); WO 03 / 050531 of Algonomics N.V. and Ablynx N.V.; WO 01 / 90190 by the National Research Council of Canada; WO 03 / 025020 (= EP 1433793) by the Institute of Antibodies; as well as WO 04 / 041867, WO 04 / 041862, WO 04 / 041865, WO 04 / 041863, WO 04 / 062551, WO 05 / 044858, WO 06 / 40153, WO 06 / 079372, WO 06 / 122786, WO 06 / 122787 and WO 06 / 122825, by Ablynx N.V. and the further published patent applications by Ablynx N.V. Reference is also made to the further prior art mentioned in these applications, and in particular to the list of references mentioned on pages 41-43 of the International application WO 06 / 040153, which list and references are incorporated herein by reference. As described in these references, Nanobodies (in particular VHH sequences and partially humanized Nanobodies) can in particular be characterized by the presence of one or more “Hallmark residues” in one or more of the framework sequences. A further description of the Nanobodies, including humanization and / or camelization of Nanobodies, as well as other modifications, parts or fragments, derivatives or “Nanobody fusions”, multivalent constructs (including some non-limiting examples of linker sequences) and different modifications to increase the half-life of the Nanobodies and their preparations can be found e.g. in WOBaLa / PETTRACER / 880
[0082] 08 / 101985 and WO 08 / 142164. For a further general description of Nanobodies, reference is made to the prior art cited herein, such as e.g., described in WO 08 / 020079 (page 16).
[0083] “Domain antibodies”, also known as “Dabs” , “Domain Antibodies”, and “dAbs” (the terms “Domain Antibodies” and “dAbs” being used as trademarks by the GlaxoSmithKline group of companies) have been described in e.g., EP 0368684, Ward et al. (Nature 341: 544-546, 1989), Holt et al. (Tends in Biotechnology 21: 484-490, 2003) and WO 03 / 002609 as well as for example WO 04 / 068820, WO 06 / 030220, WO 06 / 003388 and other published patent applications of Domantis Ltd. Domain antibodies essentially correspond to the VH or VL domains of non-camelid mammalians, in particular human 4-chain antibodies. In order to bind an epitope as a single antigen binding domain, i.e., without being paired with a VL or VH domain, respectively, specific selection for such antigen binding properties is required, e.g. by using libraries of human single VH or VL domain sequences. Domain antibodies have, like VHHs, a molecular weight of approximately 13 to approximately 16 kDa and, if derived from fully human sequences, do not require humanization for e.g. therapeutical use in humans.
[0084] It should also be noted that single variable domains can be derived from certain species of shark (for example, the so-called “IgNAR domains”, see for example WO 05 / 18629).
[0085] Thus, in the meaning of the present invention, the term “immunoglobulin single variable domain” or “single variable domain” comprises polypeptides which are derived from a non-human source, preferably a camelid, preferably a camelid heavy chain antibody. They may be humanized, as previously described. Moreover, the term comprises polypeptides derived from non-camelid sources, e.g. mouse or human, which have been “camelized”, as e.g., described in Davies and Riechmann (FEBS 339: 285-290, 1994; Biotechnol. 13: 475-479, 1995; Prot. Eng. 9: 531-537, 1996) and Riechmann and Muyldermans (J. Immunol. Methods 231: 25-38, 1999).
[0086] For numbering of the amino acid residues of an IVD different numbering schemes can be applied. For example, numbering can be performed according to the AHo numbering scheme for all heavy (VH) and light chain variable domains (VL) given by Honegger, A. and Pluckthun, A. (J. Mol. Biol. 309, 2001), as applied to VHH domains from camelids. Alternative methods for numbering the amino acid residues of VH domains, which can also be applied in an analogous manner to VHH domains, are known in the art. For example, the delineation of the FR and CDR sequences can be done by using the Kabat numbering system as applied to VHH domains from camelids in the article of Riechmann, L. and Muyldermans, S., 231(1-2), J Immunol Methods.
[0087] 1999. Determination of CDR regions may also be done according to different methods. In the CDR determination according to Kabat, FR1 of a VHH comprises the amino acid residues at positions 1-30, CDR1 of a VHH comprises the amino acid residues at positions 31-35, FR2 of a VHH comprises the amino acids at positions 36-49, CDR2 of a VHH comprises the amino acid residues at positions 50-65, FR3 of a VHH comprises the amino acid residues at positions 66-BaLa / PETTRACER / 880
[0088] 94, CDR3 of a VHH comprises the amino acid residues at positions 95-102, and FR4 of a VHH comprises the amino acid residues at positions 103-113.
[0089] It should be noted that - as is well known in the art for VH domains and for VHH domains - the total number of amino acid residues in each of the CDRs may vary and may not correspond to the total number of amino acid residues indicated by the Kabat numbering or AHo numbering (that is, one or more positions according to the Kabat numbering or AHo may not be occupied in the actual sequence, or the actual sequence may contain more amino acid residues than the number allowed for by the Kabat numbering or AHo numbering). This means that, generally, the numbering according to Kabat or AHo may or may not correspond to the actual numbering of the amino acid residues in the actual sequence. The total number of amino acid residues in a VH domain and a VHH domain will usually be in the range of from 110 to 120, often between 112 and 115. It should however be noted that smaller and longer sequences may also be suitable for the purposes described herein.
[0090] Immunoglobulin single variable domains such as Domain antibodies and Nanobodies (including VHH domains) can be subjected to humanization. In particular, humanized immunoglobulin single variable domains, such as Nanobodies (including VHH domains) may be immunoglobulin single variable domains that are as generally defined for in the previous paragraphs, but in which at least one amino acid residue is present (and in particular, at least one framework residue) that is and / or that corresponds to a humanizing substitution (as defined herein). Potentially useful humanizing substitutions can be ascertained by comparing the sequence of the framework regions of a naturally occurring VHH sequence with the corresponding framework sequence of one or more closely related human VH sequences, after which one or more of the potentially useful humanizing substitutions (or combinations thereof) thus determined can be introduced into said VHH sequence (in any manner known per se, as further described herein) and the resulting humanized VHH sequences can be tested for affinity for the target, for stability, for ease and level of expression, and / or for other desired properties.
[0091] Immunoglobulin single variable domains such as Domain antibodies and Nanobodies (including VHH domains and humanized VHH domains), can also be subjected to affinity maturation by introducing one or more alterations in the amino acid sequence of one or more CDRs, which alterations result in an improved affinity of the resulting immunoglobulin single variable domain for its respective antigen, as compared to the respective parent molecule. Affinity-matured immunoglobulin single variable domain molecules of the invention may be prepared by methods known in the art, for example, as described by Marks et al. (Biotechnology 10:779-783, 1992), Barbas, et al. (Proc. Nat. Acad. Sci, USA 91: 3809-3813, 1994), Shier et al. (Gene 169: 147-155, 1995), Yelton et al. (Immunol. 155: 1994-2004, 1995), Jackson et al. (J. Immunol. 154: 3310-9, 1995), Hawkins etal. (J. Mol. Biol. 226: 889896, 1992), Johnson and Hawkins (Affinity maturation of antibodies using phage display, Oxford University Press, 1996).BaLa / PETTRACER / 880
[0092] The process of designing / selecting and / or preparing a polypeptide, starting from an immunoglobulin single variable domain such as a Domain antibody or a Nanobody, is also referred to herein as “formatting” said immunoglobulin single variable domain; and an immunoglobulin single variable domain that is made part of a polypeptide is said to be “formatted” or to be “in the format of” said polypeptide. Examples of ways in which an immunoglobulin single variable domain can be formatted and examples of such formats will be clear to the skilled person based on the disclosure herein; and such formatted immunoglobulin single variable domain form a further aspect of the invention.
[0093] The terms “galectin-10” or gal10 or Gal10 or “crystalized gal10” or “crystalized galectin-10” are used interchangeable in this application, in particular when the embodiment or aspect or claim refers to VHH antibodies which bind to for example galectin-10. The VHH antibodies herein both bind with the recombinant galectin-10 and with the crystalized form of galectin-10 (also called Charcot Leyden crystals, or CLC crystals). Specifically the recombinant galectin-10 is produced as a dimer comprising a His-tag which cannot form CLC crystals. Only after cleavage of the His-tag with the TEV protease (herein) then the untagged galectin-10 dimers can form crystals at a high concentration.
[0094] The term “detection label” refers to a chemical moiety that can be covalently attached to an antibody and that functions to provide a detectable signal. Examples of such labels include fluorescent moieties, chemiluminescent moieties, bioluminescent moieties, nanoparticles, magnetic particles, metal-containing particles, and radiolabels, such as radionuclide tracers. The term “nanoparticle” as used herein refers to a particle having a size parameter measured on a nanometer scale, i.e. below 1 micron, and typically below 500 nm. For example, a nanoparticle has a longest dimension below 1 micron in length, such as 1 nm to 500 nm, 5 nm to 100 nm, 10 nm to 90 nm, 20 nm to 80 nm, 30 nm to 75 nm, 40 nm to 70 nm, 50 nm to 60 nm, such as a longest dimension of about 1 nm, 5 nm, 10 nm, 15 nm, 20 nm, 25 nm, 30 nm, 35 nm, 40 nm, 45 nm, 50 nm, 55 nm, 60 nm, 65 nm, 70 nm, 75 nm, 80 nm, 85 nm, 90 nm, 95 nm, or 100 nm. The nanoparticles can have any shape, such as spheres, rods, cubes, wires, plates, irregular, or mixed shapes. The nanoparticles can be made of a synthetic or natural material, or combination thereof, which is directly imaged, or may themselves include a detection label. The nanoparticles may contain, or consist of, a metal, such as but not limited to, gold, iron, zinc, silver, copper, cobalt, cadmium, nickel, gadolinium, chromium, tin, aluminum, palladium, manganese, titanium, an oxide of any thereof, alloys or mixtures of any two or more thereof. The particles may be, or include, carbon, such as carbon nanotubes.
[0095] The term “bifunctional chelator” refers to a chemical moiety that attaches an antibody to a radionuclide label. Bifunctional chelators include 1) a chelator moiety functional to bind a radionuclide label and 2) a reactive functional group. Bifunctional chelators function by complexing a radionuclide with the chelator moiety and by covalently attaching the chelatorBaLa / PETTRACER / 880
[0096] moiety (and complexed radionuclide) to an antibody via reaction of the reactive functional group with a corresponding reactive functional group of the antibody.
[0097] For example, bifunctional chelators may be covalently attached to a primary amine group, a hydroxyl group, and / or a cysteine amino acid of an antibody. Examples of suitable chelator moieties include: desferrioxamine (DFO*NCS), 1,4,7-Triazacyclononane (TACN); 1,4,7,10-Tetraazacyclododecane (Cyclen); 1,4,7,10-Tetraazacyclododecane-1,7-diacetic acid (D02A); 1.4.7.10-Tetraazacyclododecane-1,4,7-triacetic acid trisodium salt (D03A); 1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA); 1,4,7,10-Tetraazacyclododecane- 1.4.7.10-tetra(methylene phosphonic acid) (DOTP); 1,4, 8, 11-Tetraazacyclotetradecane-1, 4, 8, ll-tetraacetic acid (TETA); 2,2',2”,2”’-(l,4,8,ll-tetraazacyclotetradecane-1,4,8,1 1-tetrayl)tetraacetamide (TETAM); 1,4,7,10-Tetrakis(carbamoylmethyl)-1,4,7,10-tetraazacyclododecane (DOTAM); 2,2',2”-(1,4,7,10-tetraazacyclododecane-1,4,7-triyl)triacetamide (D03AM); 1 ,8-Diamino-3,6, 10, 13, 16, 19-hexaazabicyclo[6,6,6]-eicosane (DiAmSar); 1,4, 8,1 1-Tetraazabicyclo[6.6.2]hexadecane (CB-Cyclam); 2,2'-(1,4,8, 1 1-tetraazabicyclo[6.6.2]hexadecane-4,1 1 -diyl)diacetic acid (CB-TE2A); 1,4,7-Triazacyclononane-1,4,7-triacetic acid (NOTA); 1,4,7-Triazacyclononane- 1,4,7 -tri(methylene phosphonic acid) (NOTP); 3-(((4,7-bis((hydroxy(hydroxymethyl)phosphoryl)methyl)-1,4,7-triazonan-l-yl)methyl)(hydroxy)phosphoryl)propanoic acid (NOPO); 2,2',2”-(1,4,7-triazacyclononane-1,4,7-triyl)triacetamide (NOTAM) ; 2, 2', 2”, 2”’ - ((((carboxymethyl)azanediyl)bis(ethane-2,l-diyl))bis(azanetriyl))tetraacetic acid (DTPA); 3,6,9, 15-Tetraazabicyclo[9.3.1]pentadeca-l(15),11,13-triene-3,6,9-triacetic acid (PCTA); 2,2',2”,2”’-(1,4,7,10-tetraazacyclotridecane- 1.4.7.10-tetrayl)tetraacetic acid (TRITA); 2,2',2”,2”’-(1,4,7,10-tetraazacyclotridecane-1,4,7,10-tetrayl)tetraacetamide (TRITAM); 2,2',2”-(1,4,7,10-tetraazacyclotridecane-1,4,7-triyl)triacetamide (TRITRAM); and 3,3',3”-(((1,4,7-triazonane-1,4,7-triyl)tris(methylene))tris(hydroxyphosphoryl))tripropanoic acid (TRAP); or a combination of any two or more thereof.
[0098] Examples of suitable reactive functional groups capable of attaching a chelator moiety to a primary amine group, a hydroxyl group, and / or a cysteine amino acid of an antibody are known to those of skill in the art (see e.g., Denardo et al, 1998, Clin Cancer Res. 4(10):2483-90; Peterson et al, 1999, Bioconjug. Chem. 10(4):553-7; and Zimmerman et al, 1999, Nucl. Med. Biol. 26(8): 943-50).
[0099] Diagnostic Compositions
[0100] A diagnostic composition according to aspects of the present disclosure includes a labeled- ISD conjugate in an amount in the range of about 0.1 -99% and a pharmaceutically acceptable carrier. A diagnostic composition of the present disclosure, for in vivo use, is thus also a pharmaceutical composition and may be in any dosage form suitable for administration to a subject, illustrativelyBaLa / PETTRACER / 880
[0101] including solid, semi-solid and liquid dosage forms such as tablets, capsules, powders, granules, pills, solutions, suspensions, and gels. Liposomes and emulsions are well-known types of pharmaceutical formulations that can be used to deliver a composition of the present disclosure. Pharmaceutical compositions of the present disclosure generally include a pharmaceutically acceptable carrier such as an excipient, diluent and / or vehicle. Delayed release formulations of compositions and delayed release systems, such as semipermeable matrices of solid hydrophobic polymers can be used.
[0102] The term “pharmaceutically acceptable carrier” refers to a carrier which is suitable for use in a subject without undue toxicity or irritation to the subject and which is compatible with other ingredients included in a pharmaceutical composition.
[0103] Pharmaceutically acceptable carriers, methods for making pharmaceutical compositions and various dosage forms, as well as modes of administration are well-known in the art, for example as detailed in F.V. Allen, Jr. et al., Ansel’s Pharmaceutical Dosage Forms and Drug Delivery Systems, 8th Ed., Philadelphia, PA: Fippincott, Williams & Wilkins, 2004; A. R. Gennaro, Remington: The Science and Practice of Pharmacy, Fippincott Williams & Wilkins, 21st ed., 2005; and J. G. Hardman et al., Goodman & Gilman's The Pharmacological Basis of Therapeutics, McGraw-Hill Professional, 10th ed., 2001.
[0104] A solid dosage form for suspension in a liquid prior to administration illustratively includes capsules, tablets, powders, and granules. In such solid dosage forms, one or more active agents, is admixed with at least one carrier illustratively including a buffer such as, for example, sodium citrate or an alkali metal phosphate illustratively including sodium phosphates, potassium phosphates and calcium phosphates; a filler such as, for example, starch, lactose, sucrose, glucose, mannitol, and silicic acid; a binder such as, for example, carboxymethylcellulose, alginates, gelatin, polyvinylpyrrolidone, sucrose, and acacia; a humectant such as, for example, glycerol; a disintegrating agent such as, for example, agar-agar, calcium carbonate, plant starches such as potato or tapioca starch, alginic acid, certain complex silicates, and sodium carbonate; a solution retarder such as, for example, paraffin; an absorption accelerator such as, for example, a quaternary ammonium compound; a wetting agent such as, for example, cetyl alcohol, glycerol monostearate, and a glycol; an adsorbent such as, for example, kaolin and bentonite; a lubricant such as, for example, talc, calcium stearate, magnesium stearate, a solid polyethylene glycol or sodium lauryl sulfate; a preservative such as an antibacterial agent and an antifungal agent, including for example, sorbic acid, gentamycin and phenol; and a stabilizer such as, for example, sucrose, EDTA, EGTA, and an antioxidant.
[0105] A composition for parenteral administration may be formulated as an injectable liquid. Liquid dosage forms for injection include one or more active agents and a pharmaceutically acceptable carrier formulated as an emulsion, solution, or suspension. A liquid dosage form for injection including a composition of the present disclosure may further include a stabilizer, a wettingBaLa / PETTRACER / 880
[0106] agent, an emulsifying agent, a suspending agent or any two or more thereof. Examples of suitable aqueous and nonaqueous pharmaceutically acceptable carriers include water, a buffer, ethanol, polyols such as propylene glycol, polyethylene glycol, glycerol, and the like, suitable mixtures thereof; vegetable oils such as olive oil; and injectable organic esters such as ethyloleate. Proper fluidity can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of a desirable particle size in the case of dispersions, and / or by the use of a surfactant, such as sodium lauryl sulfate. A stabilizer is optionally included such as, for example, sucrose, EDTA, EGTA, and an antioxidant.
[0107] Detailed information concerning customary ingredients, equipment and processes for preparing dosage forms is found in Pharmaceutical Dosage Forms: Tablets, eds. H. A. Lieberman et al., New York: Marcel Dekker, Inc., 1989; and in L.V. Allen, Jr. et al. , Ansel’s Pharmaceutical Dosage Forms and Drug Delivery Systems, 8th Ed., Philadelphia, PA: Lippincott, Williams & Wilkins, 2004; A. R. Gennaro, Remington: The Science and Practice of Pharmacy, Lippincott Williams & Wilkins, 21st ed., 2005, particularly chapter 89; and J. G. Hardman et al., Goodman & Gilman's The Pharmacological Basis of Therapeutics, McGraw-Hill Professional, 10th ed., 2001.
[0108] Methods for Imaging
[0109] In one or more embodiments, methods for imaging are disclosed herein. In embodiments, methods for imaging include: (a) administering a labeled-ISD conjugate to a subject, wherein the labeled- ISD conjugate includes: an ISD that specifically recognizes and binds to the crystalline form of galectin 10, and at least one detection label conjugated to the ISD, wherein the at least one detection label includes a radionuclide tracer, a fluorophore, a nanoparticle, or a combination or any two or more thereof; and (b) detecting the presence of the labeled- ISD conjugate in the subject in vivo by imaging. In embodiments, the labeled-ISD conjugate is as described herein with regard to ISD conjugates. In further embodiments, the ISD and the at least one detection label are as described herein with regard to antibody conjugates.
[0110] In embodiments, the methods for imaging include detecting the presence of the labeled-ISD conjugate in the subject in vivo by imaging. In embodiments, the presence of the labeled-ISD conjugate is detected in real time. In embodiments, the presence of the labeled-ISD conjugate is detected non-invasively and / or minimally-invasively.
[0111] According to aspects of the present disclosure, an ISD conjugate is an imaging agent which can be used to visualize galectin 10 crystals, such as in diagnostic procedures. Imaging can be performed by many procedures well-known to those having ordinary skill in the art, for example, by positron emission tomography (PET), single photon emission computed tomography (SPECT), Cerenkov imaging, photoacoustic imaging, ultrasound imaging, optical coherence tomography, optical imaging, including fluorescence imaging, magnetic resonance imaging, magnetic particle imaging, bioluminescence imaging, or a combination of any two or more thereof.BaLa / PETTRACER / 880
[0112] In embodiments, the methods include administering a labeled-ISD conjugate to a subject. In embodiments, the methods include administering an effective amount of a labeled-ISD conjugate to a subject. The labeled-ISD conjugate may be administered by any suitable route known to those of ordinary skill in the art. In embodiments, administration of the labeled-ISD conjugate is by intravenous, intraarterial, intraperitoneal, intramuscular, subcutaneous, intrapleural, intrathecal, perfusion through a regional catheter, and / or direct intralesional injection. In embodiments wherein the labeled-ISD conjugate is administered by injection, the administration may be by continuous infusion, by single bolus, and / or by multiple boluses. In some embodiments, administering the radiolabeled-ISD conjugate is non-immunogenic to the subject. According to embodiments, administering a labeled-ISD conjugate to a subject includes administering a pharmaceutical composition including the labeled-ISD conjugate and a pharmaceutically acceptable carrier.
[0113] In embodiments, the subject is a mammal. In some embodiments, the subject is a mammal selected from: humans, non-human primates, canines, felines and equines. According to particular embodiments, the subject is a human.
[0114] In embodiments, the labeled-ISD conjugate administered to a subject includes a radionuclide tracer. In some embodiments, the labeled- ISD conjugate administered to a subject includes a labeled-ISD conjugate wherein the label is a radionuclide tracer only, i.e. without a fluorophore or nanoparticle. In some embodiments, the labeled-ISD conjugate administered to a subject includes a labeled-ISD conjugate wherein the label is a fluorophore only, i.e. without a radionuclide tracer or nanoparticle. In some embodiments, the labeled-ISD conjugate administered to a subject includes a labeled- ISD conjugate wherein the label is a nanoparticle only, i.e. without a radionuclide tracer or fluorophore.
[0115] In embodiments, the radionuclide tracer is selected from:11C,13N,150,18F,44Sc,45Ti,52Mn,64Cu,68Ga,44Sc,76Br,82Rb,86Y,89Zr,90Y,99mTc,111In,124I,131l,43K,52Fe,57Co,67Cu,67Ga,77Br,81Rb,81mKr,87mSr,89Zr,113mln,123l,125l,127Cs,129Cs,132l,177Lu,186Re,197Hg,203Pb.206Bi,82Sr,188Re,60Cu,61Cu,62Cu,225Ac,225Ra, and a combination of any two or more thereof.
[0116] In embodiments, the imaging is positron emission tomography (PET), and the radionuclide tracer is68Ga,18F,44Sc,f>4Cu,86Y,89Zr,124l,or89Zr. In illustrative, non limiting embodiments, the radionuclide tracer is89Zr.
[0117] In embodiments, the imaging is single positron emission computed tomography (SPECT), and the radionuclide tracer is67Ga,111ln,186Re,188Re,90Y,177Lu, or99mTc.
[0118] In embodiments of methods for imaging, the labeled-ISD conjugate administered to a subject includes a fluorophore. In embodiments, the fluorophore is a fluorescent dye.
[0119] In embodiments wherein the labeled-ISD conjugate includes a radionuclide tracer, the presence of the labeled-ISD conjugate may be detected in vivo by PET imaging, SPECT imaging, orBaLa / PETTRACER / 880
[0120] combination thereof. In embodiments wherein the radionuclide tracer is selected from11C,13N,150,18F,64Cu,68Ga,44Sc,76Br,82Rb,86Y,89Zr,124l, or a combination of any two or more thereof, the presence of the labeled-ISD conjugate may be detected in vivo by PET imaging. In illustrative, non-limiting embodiments for positron emission tomography (PET), the radionuclide tracer is68Ga,18F,64Cu,124l, or89Zr. In embodiments wherein the radionuclide tracer is selected from99mTc,67Ga,1111 n,131l,186Re,188Re,177Lu, or a combination of any two or more thereof, the presence of the labeled-antibody conjugate may be detected in vivo by SPECT imaging. In illustrative, non-limiting embodiments for single positron emission computed tomography (SPECT), the radionuclide tracer is67Ga,111ln,177Lu, or99mTc.
[0121] In embodiments wherein the labeled ISD conjugate includes a fluorophore, the presence of the labeled-ISD conjugate may be detected in vivo by optical imaging. Various in vivo optical imaging techniques are known to those of ordinary skill in the art and their potential applicability to imaging-guided diagnostic and surgical methods has been proposed in several preclinical studies. In embodiments, in vivo optical imaging is selected from confocal microscopy, planar imaging, fluorescence molecular tomography, complete projection tomography, fluorescence tomography direct imaging, two-photon in vivo imaging or a combination of any two or more thereof. In further embodiments, planar imaging is selected from epi-illumination (i.e. photographic) imaging, trans-illumination imaging, tomographic imaging, or a combination of any two or more thereof.
[0122] In embodiments wherein the presence of the labeled-ISD conjugate is detected by in vivo optical imaging, the fluorophore may be selected such that it emits fluorescence in the visible or nearinfrared region. In illustrative, non-limiting embodiments, fluorophores emitting fluorescence in the visible or near-infrared region may be selected from fluorescein, Cy2, Cy3, Cy3B, Cy3.5, Cy5, Cy5.5, Cy7, Texas Red® (Molecular Probes, Inc., Eugene, OR), AlexaFluor® (Molecular Probes, Inc., Eugene), AlexaFluor 350, AlexaFluor 405, AlexaFluor 430, AlexaFluor 488, AlexaFluor 500, AlexaFluor 532, AlexaFluor 546, AlexaFluor 568, AlexaFluor 594, AlexaFluor 610, AlexaFluor 633, AlexaFluor 647, AlexaFluor 660, AlexaFluor 680, AlexaFluor 700, AlexaFluor 750, BODIPY FF, BODIPY R6G, BODIPY TMR, BOPDIPY 530 / 550, BODIPY 558 / 568, BODIPY 564 / 570, BODIPY 576 / 589, BODIPY 581 / 591, BODIPY 630 / 650, BODIPY 650 / 665, Rhodamine Green™-X (Molecular Probes, Inc.), Rhodamine Red™-X (Molecular Probes, Inc.), Rhodamine 6G, TMR, TAMRA™ (Applied Biosystems), or a combination of any two or more thereof.
[0123] In embodiments the presence of the labelled ISD conjugate is detected by in vivo photoacoustic imaging. In illustrative, non-limiting embodiments, photoacoustic dyes included in the conjugate may be selected from Methylene blue, Evan's blue, Trypan blue, Patent blue, Indocyanine Green, IRDye800CW, DiR, Cy7, Cy7.5, and porphyrins or a combination of any two or more thereof.BaLa / PETTRACER / 880
[0124] In embodiments wherein the labeled ISD conjugate includes a combination of a radionuclide tracer and a fluorophore, the presence of the labeled-ISD conjugate may be detected in vivo by a combination of PET or SPECT and optical imaging.
[0125] In embodiments wherein the labeled ISD conjugate includes a combination of a radionuclide tracer and a fluorophore, the presence of the labelled ISD conjugate may be detected in vivo by a combination of PET or SPECT and photoacoustic imaging.
[0126] In embodiments the presence of the labeled-ISD conjugate may be detected in vivo by a combination of any two or more of: PET, SPECT, Cerenkov imaging, photoacoustic imaging, ultrasound imaging, optical coherent tomography, magnetic resonance imaging, magnetic particle imaging, optical imaging, including fluorescence imaging, and / or bioluminescence imaging.
[0127] According to embodiments, a method for imaging a subject includes 1) administering a labeled-ISD conjugate to a subject, wherein the labelled antibody conjugate includes: an ISD that specifically binds to the crystalline form of galectin 10, and a detection label conjugated to the ISD, wherein the detection label is a radionuclide tracer, nanoparticle, and / or fluorophore; and 2) detecting the presence of the labeled-ISD conjugate in the subject in vivo by imaging.
[0128] The present invention also provides use of a galectin-10 ISD or ISVD for the detection of galectin-10 in a sample obtained from a patient. The ISD or ISVD with a specificity for galectin 10 are typically used to detect crystalline galectin-10. As noted in the introduction, galectin-10 crystals or CLC crystals have been observed in patients having a number of different diseases and conditions. It follows, that the patient sample may be isolated from a subject having or suspected of having any one of the following diseases or conditions: asthma, chronic rhinosinusitis, celiac disease, helminth infection, gastrointestinal eosinophilic inflammation, cystic fibrosis (CF), allergic bronchopulmonary aspergillosis (ABPA), Churg-Straus vasculitis, chronic eosinophilic pneumonia, or acute myeloid leukemia. The detection of crystalline galectin-10 in the patient sample may be used to diagnose the disease or condition in the subject from which the sample was obtained. The sample may be any suitable patient sample, for example any fluid or tissue in which CLCs are observed in a disease state. In certain embodiments, the sample is a tissue sample obtained from a polyp, for example a nasal polyp. In certain embodiments, the sample is a mucus sample. In such embodiments, the detection of crystalline galectin-10 in the mucus sample using the I D or ISVD molecules of the invention may be used to detect or diagnose chronic rhinosinusitis. In preferred embodiments, the patient sample is a sputum sample. In such embodiments, the detection of crystalline galectin-10 in the sputum sample using the ISD or ISVD molecules of the invention may be used to detect or diagnose asthma.BaLa / PETTRACER / 880
[0129] In a particular embodiment the invention provides nucleic acid molecules encoding the IVD or ISVD sequences as described herein before.
[0130] In yet another embodiment the invention provides a vector comprising a nucleic acid molecule encoding the IVD or ISVD sequences as described herein before.
[0131] In yet another embodiment the invention provides a host cell comprising a nucleic acid sequence encoding the IVD or ISVD sequences as described herein or a vector comprising a nucleic acid sequence encoding the IVD or ISVD sequences as described herein.
[0132] Host cells can be higher eukaryotic cells or lower eukaryotic cells or prokaryotic cells.
[0133] A “higher eukaryotic cell” as used herein refers to eukaryotic cells that are not cells from unicellular organisms. In other words, a higher eukaryotic cell is a cell from (or derived from, in case of cell cultures) a multicellular eukaryote such as a human cell line or another mammalian cell line (e.g. a CHO cell line). Typically, the higher eukaryotic cells will not be fungal cells. Particularly, the term generally refers to mammalian cells, human cell lines and insect cell lines. More particularly, the term refers to vertebrate cells, even more particularly to mammalian cells or human cells. The higher eukaryotic cells as described herein will typically be part of a cell culture (e.g. a cell line, such as a HEK or CHO cell line), although this is not always strictly required (e.g. in case of plant cells, the plant itself can be used to produce a recombinant protein).
[0134] By “lower eukaryotic cell” a filamentous fungus cell or a yeast cell is meant. Yeast cells can be from the species Saccharomyces (e.g. Saccharomyces cerevisiae), Hansenula (e.g. Hansenula polymorpha), Arxula (e.g. Arxula adeninivorans), Yarrowia (e.g. Yarrowia lipolytica), Kluyveromyces (e.g. Kluyveromyces lactis), or Komagataella phaffii (Kurtzman, C.P. (2009) J Ind Microbiol Biotechnol. 36(11) which was previously named and better known under the old nomenclature as Pichia pastoris and also further used herein. According to a specific embodiment, the lower eukaryotic cells are Pichia cells, and in a most particular embodiment Pichia pastoris cells. In specific embodiments the filamentous fungus cell is Myceliopthora thermophila (also known as C1 by the company Dyadic), Aspergillus species (e.g. Aspergillus nidulans, Aspergillus niger, Aspergillus oryzae, Aspergillus japonicus), Fusarium species (e.g. Fusarium venenatum), Hypocrea and Trichoderma species (e.g. Trichoderma reesei).
[0135] “Prokaryotic cells” typically refer to non-pathogenic prokaryotes like bacterial cells such as for example E. coli, Lactococcus and Bacillus species.BaLa / PETTRACER / 880
[0136] Examples
[0137] 1. Production of VHH antibodies specifically binding crystalline qalectin 10 and testing the dissolution of crystalline galectin 10
[0138] Five (5) different VHH antibodies (abbreviated herein as Gal 10 VHHs) specifically binding to the crystalline form of galectin 10 were selected from the application WO2019197675 (see Table 36 therein): i) 13C03 depicted herein as SEQ ID NO: 1, ii) 15A02 depicted herein as SEQ ID NO: 2, iii) 13C06 depicted herein as SEQ ID NO: 3, iv) 1D06 depicted herein as SEQ ID NO: 4 and v) 13E09 depicted herein as SEQ ID NO: 5. Amino acid residue mutations (Q1E, A14P, K87R, Q108L) were introduced in these sequences for investigating effects on increased stability and possible improved biophysical characteristics. The nucleotide sequences of these 5 modified VHH sequences were subcloned into an E. coli expression vector under control of an IPTG-inducible lac promoter, in frame with an N-terminal PelB signal peptide and a C-terminal HIS6 tag or untagged for production of untagged and C-terminal His6 tagged VHHs. VHHs were produced in TG-1 E.coli at 0.25 L scale, and purified from the periplasmatic fraction using standard immune affinity chromatography (IMAC) on the His-tag on 2 mL Ni Sepharose FastFlow columns, followed by desalting step on PD-10 columns, according to established procedures (Pardon et al. (2014) Nat. Protocols 9:674). Tagless VHHs were purified on protein A resins. For PET imaging studies, VHHs were subsequently purified by preparative size exclusion chromatography (SEC) on a Superdex 75 size exclusion column equilibrated in 50 mM MES pH 6.0, 150 mM NaCI, and concentrated to 2 mg / mL. From the panel, only P0190002 (13C03) was found to bind protein A, and could be successfully purified as tagless VHH. The purity and integrity of the VHHs was analysed by SDS-PAGE analysis, and the correct molecular mass was confirmed by mass spectrometry analysis. The endotoxin levels were assessed in a LAL test.
[0139] To assess the capacity of different anti-Gal VHHs to dissolute CLCs, the panel of VHHs was analyzed in time-lapse spinning disc microscopy (VIB imaging core). Since fluorescent CLCs are used in animal models, we tested whether fluorescent CLCs would be equally targeted as normal CLCs, and whether these would provide an easier method for quantification. VHHs were tested at 60 pM concentration (final) with 1.75 pg CLCs, with as references an irrelevant control VHH antibody (IRR VHH), PBS only, and a research tool Fab antibody (disclosed in WQ2019197675 and Persson EK et al (2019) Science 24, 364) depicted as 1D11 (35 pM) in Table 1. All experiments were carried out in triplicates.
[0140] Results are depicted in Table 1. With the exception of VHH 13C03, all anti-Gal 10 VHHs showed fast dissolution of CLCs, with 90% dissolution reached between 10 and 40 minutes. We did not observe any apparent difference in CLC dissolution rate with FITC labeled CLCs vs non-labelled CLCs.BaLa / PETTRACER / 880
[0141] % CLC 1 D11 1D06-His 13C03-His 13C06-His 13E09-His 15A02-His IRRVHH dissolution Fab P01900006 P01900007 P01900008 P01900009 P01900010 IRR00006 EC50 (min) 35 10 >120 3 10 8 E
[0142]
[0143] C90 (min) 100 40 >120 10 24 30 Table 1: With the exception of VHH 13C03, all anti-Gal10 VHHs showed fast dissolution of CLCs, with 90% dissolution reached between 10 and 40 minutes. We did not observe any apparent difference in CLC dissolution rate with FITC labeled CLCs vs non-labelled CLCs.
[0144] 2. Binding of the different VHH nanobodies to qalectin 10
[0145] To confirm the binding to galectin 10 the kinetic binding parameters of the different Gal10 VHHs to human Gal 10 protein were assessed in Biolayer interferometry (BLI) using an OctetRED96 system (Sartorius). In this experiment, in-house biotinylated Gal10 protein (without tags) was captured onto pre-soaked streptavidin biosensors (SA), at a loading concentration of 5 ug / mL in 0.2 mL in black non-binding microtiter plates. Loading level was set to a fixed level of 1 nm. Biosensors were dipped into kinetic buffer for 2 minutes to set a stable baseline, followed by subsequent association of antibody constructs with 2-fold dilution range for 150 seconds. Dissociation into kinetic buffer was monitored for 300-600 seconds. Biosensors were regenerated at the end of the dissociation step using 1 mM glycine (pH 1.7) buffer. Traces were processed using background subtraction of parallel sensors, and curve fitting was done using 1:1 Langmuir fitting on individual traces. Average KD values were calculated using global fitting, using Rmax linked for the group fitting. Results are shown in table 2. All Gal10 VHHs bound well to Gal10, with KD values in low nM range.
[0146] ID KD KD Error kon(1 / Ms) kon Error kdis(1 / s) kdis Error (M)
[0147] 1D11 Fab 6.38E-09 8.64E-11 4.69E+05 6.06E+03 2.99E-03 1.22E-05 13C03 | P01900002 3.29E-09 1.06E-10 1.11 E+06 3,41 E+04 3.63E-03 3.44E-05 13C03-His P01900007 3.98E-09 5.77E-11 6.45E+05 7.92E+03 2.57E-03 1 ,98E-05 13C06-His I P01900008 3.35E-09 3.54E-11 2.66E+05 1 ,62E+03 8,91 E-04 7.69E-06 13E09-His P01900009 2.47E-08 3.41 E-10 3.43E+05 4.39E+03 8.45E-03 4.34E-05
[0148]
[0149] 15A02-His I P01900010 2.80E-09 2.54E-11 3.24E+05 1 ,78E+03 9.07E-04 6.56E-06
[0150] Table 2: Binding parameters to Gal10 in BLI. Biotinylated Gal10 was captured on streptavidin biosensors, and binding of a concentration range of Gal 10 VHHs or 1D11 Fab was assessed in Octet96. Average KD values after 1:1 fitting of background subtracted traces are shown.
[0151] 3.Gal10 VHHs bind to different epitopes on Galectin-10
[0152] We showed that VHH antibody 13C03 binds well to Gal10 in BLI, while it surprisingly lacks CLC dissolution capacity. The thermodynamic parameters and binding affinity of 13C03 to Gal 10BaLa / PETTRACER / 880
[0153] (without tags) and N-terminally His-tagged Gal10 proteins was assessed via iso-thermal calorimetry.
[0154] ITC experiments were performed using a MicroCai PEAQ-ITC instrument at 298 K. His-Gal10 dimer (Mw of 41.18 kDa) was subjected to cleavage by TEV protease overnight at room temperature, followed by removal of the His-tag by IMAC, to generate untagged Gal10 dimer (Mw of 33.28 kDa). Gal10 or His-Gal10 were loaded in the ITC sample cell at a concentration of 6.7 pM. 13C03 (P0190002) (134 pM ,1.76 mg / mL) was titrated in the sample cell by consecutive 2 pL syringe injections with a spacing of 150 s, stirring at a speed of 750 rpm. Data were analysed using PEAQ-ITC analysis software (version 1.3, Malvern) and fitted using a ‘one set of sites’ model to obtain the enthalpy change (AH), free energy change (AG), the number of binding sites (n), and affinity dissociation constant (KD). After finalization of the experiment, ITC samples were analyzed via SDS-PAGE (4-15% TGX gel), using staining-free imaging for detection of the proteins. Results are shown in Figure 2.
[0155] The crystal structures of Gal 10 VHHs 13C03 (P0190002) and 15A02 (wildtype) were generated with Gal 10 and Gal10-Y69E, a variant that is unable to form CLCs.
[0156] Results are shown in Figure 3. The structure of the Gal10: VHH-15A02 complex indicates that 15A02 binds Gal 10 at Tyr69, that is part of the crystal packing interface in CLCs. This is in agreement with the CLC dissoluting capacity of 15A02 (P01900010). In contrast, the structure of Gal10Y69E: VHH-13C03 complex indicates that 13C03 binds to an epitope on the other side of Gal10, oriented towards the N-terminus of Gal10.
[0157] 4. Sequence optimization of Gall 0 VHHs
[0158] The protein sequences of VHH sequences 15A02 (SEQ ID NO: 2), 13C06 (SEQ ID NO: 3) and 13C03 (SEQ ID NO: 1) were modified to improve them in terms of humanization towards human IGHV3 and JH germline consensus sequences, as well as exploring the possibility for improving their chemical and biophysical stability, while at the same time aiming to minimize the impact on target binding and inhibition.
[0159] Our previous unpublished sequence optimization work on VHH 15A02 indicated that 15A02 variants showed a high propensity towards aggregation at higher concentrations (i.e. > 3 mg / mL), resulting in low production yields. VHH antibody 13C06 is related to VHH antibody 15A02. 13C06 differs from 15A02 at 8 amino acid positions in the framework and CDR regions, with marked differences in charged residues in the CDRs, resulting a very different isoelectric point (I EP) which could change the biophysical properties and be an advantage during manufacturing.
[0160] Different mutant variants (modifications in the framework regions) were generated for each of the 3 VHHs (15A02, 13C06 and 13C03) (see Figure 4). Residue numbering and CDR delineations were done according to the IMGT nomenclature (Lefranc and Lefranc, 2023).BaLa / PETTRACER / 880
[0161] Residues Q1E, L2V, A14P, K95R, Q123L were introduced in the 3 different VHHs (also shown here in the tables and figures as P01900007 (13C03-His), P01900008 (13C06-His) and P01900010 (15A02-His). Several variants were made with individual positions mutated one by one, or with combined mutations. Variants were generated with a C-terminal His tag, as 15A02 and 13C06 are not binding to protein A but 13C03 is binding to protein A.
[0162] An alignment of the sequence optimized variants is shown in Figure 4.
[0163] Table 3 depicts the sequences of the sequence optimized variants.BaLa / PETTRACER / 880
[0164] ID tag description amino acid sequence EVQLVESGGGLVQPGGSLRLSCAASENSVSTYAMGWFRQAPGKEREFVAAITR
[0165] P01900001 1DO6(Q1E,K9 AGGNT YNADSVKGRFT I S RDNAENT I YLQMNS LRPEDTAVYYCAAGPRYSTI S (SEQ ID NO: 6) none 5R,Q123L) TMFPYWGQGTLVTVS S EVQLVESGGGLVQPGGSLRLSCAASGSIFSISRMGWYRQAPGKQRELVAIIFS
[0166] P01900002 13CO3(Q1E, DASTDYADSVKGRFTISRSNAKNTVYLQMNSLRPEDTAVYYCKSVLRAAGYGY (SEQ ID NO: 7) none K95R, Q123L) FNQYWGQGTLVTVS S
[0167] 13CO6(Q1E,L2 EVQLVESGGGLVQPGGSLRLSCAASSSSYSMGWFRQAPGKEREFVATISWSGG P01900003 V,A14P,K95R, FYYDDSVKGRFTVSRDNAKNTVYLQMNSLRPEDTAVYYCAAGTRFSFSYREYH (SEQ ID NO: 8) none Q123L) YWGQGTLVTVSS EVQLVESGGGLVQPGGSLRLSCAASGRTFSSYHMMWFRQAPGKEREFVAAIAW
[0168] P01900004 13EO9(Q1E,V4 RGGTYCANSVKGRCTISRDNAKDTVYLQMNSLRPEDTAVYYCAASLRYVFDPS (SEQ ID NO: 9) none L,Q5V,K95R) AMDYWGQGTLVTVS S
[0169] P01900005 15AO2(Q1E,A EVQLVESGGGLVQPGGSLRLSCAASGSSYSMGWFRQAPGKEREFVATISWSGG (SEQ ID NO: 14P, K95R, NYVDNSVKGRFTVSRDNAKNTVYLQMNSLRPEDTAVYYCAAGTQFSFSYRQYD 10) none Q123L) YWGQGTLVTVSS
[0170] P01900006 1DO6(Q1E,K9 EVQLVESGGGLVQPGGSLRLSCAASENSVSTYAMGWFRQAPGKEREFVAAITR (SEQ ID NO: 5R,Q123L)- AGGNT YNADSVKGRFT I S RDNAENT I YLQMNS LRPEDTAVYYCAAGPRYSTI S 11) HIS6 HIS6 TMFPYWGQGTLVTVS SAAHHHHHH
[0171] P01900007 13CO3(Q1E, EVQLVESGGGLVQPGGSLRLSCAASGSIFSISRMGWYRQAPGKQRELVAIIFS (SEQ ID NO: K95R, Q123L)- DASTDYADSVKGRFTISRSNAKNTVYLQMNSLRPEDTAVYYCKSVLRAAGYGY 12) HIS6 HIS6 FNQYWGQGTLVTVS SAAHHHHHH
[0172] P01900008 13CO6(Q1E,L2 EVQLVESGGGLVQPGGSLRLSCAASSSSYSMGWFRQAPGKEREFVATISWSGG (SEQ ID NO: V,A14P,K95R, FYYDDSVKGRFTVSRDNAKNTVYLQMNSLRPEDTAVYYCAAGTRFSFSYREYH 13) HIS6 Q123L)-HIS6 YWGQGTLVTVS SAAHHHHHH
[0173] P01900009 13EO9(Q1E,V4 EVQLVESGGGLVQPGGSLRLSCAASGRTFSSYHMMWFRQAPGKEREFVAAIAW (SEQ ID NO: L,Q5V,K95R)- RGGTYCANSVKGRCTISRDNAKDTVYLQMNSLRPEDTAVYYCAASLRYVFDPS 14) HIS6 HIS6 AMDYWGQGTLVTVS SAAHHHHHH
[0174] P01900010 15AO2(Q1E, EVQLVESGGGLVQPGGSLRLSCAASGSSYSMGWFRQAPGKEREFVATISWSGG (SEQ ID NO: A14P, K95R, NYVDNSVKGRFTVSRDNAKNTVYLQMNSLRPEDTAVYYCAAGTQFSFSYRQYD 15) HIS6 Q123L)-HIS6 YWGQGTLVTVS SAAHHHHHH
[0175] P01900032 EVQLVESGGGLVQPGGSLRLSCAASGSIFSISRMGWYRQAPGKQRELVAIIFS (SEQ ID NO: 13C03 (D66Y)- DASTYYADSVKGRFTISRSNAKNTVYLQMNSLRPEDTAVYYCKSVLRAAGYGY 16) HIS6 HIS6 FNQYWGQGTLVTVS SAAAHHHHHH
[0176] P01900033 EVQLVESGGGLVQPGGSLRLSCAASGSIFSISRMGWYRQAPGKQRELVAIIFS (SEQ ID NO: 13C03 (S81D)- DASTDYADSVKGRFTISRDNAKNTVYLQMNSLRPEDTAVYYCKSVLRAAGYGY 17) HIS6 HIS6 FNQYWGQGTLVTVS SAAAHHHHHH
[0177] P01900034 13C06 EVQLVESGGGLVQPGGSLRLSCAASSSSYSMGWFRQAPGKEREFVATISWSGG (SEQ ID NO: (D68A,V78I)- FYYADSVKGRFT I S RDNAKNTVYLQMNS LRPEDTAVYYCAAGTRFSFSYREYH 18) HIS6 HIS6 YWGQGT LVTVS SAAAHHHHHH
[0178] P01900035 15A02 EVQLVESGGGLVQPGGSLRLSCAASGSSYSMGWFRQAPGKEREFVATISWSGG (SEQ ID NO: (V67Y,V78I)- NYYDNSVKGRFT I S RDNAKNTVYLQMNS LRPEDTAVYYCAAGTQFSFSYRQYD 19) HIS6 HIS6 YWGQGT LVTVS SAAAHHHHHH
[0179] P01900036 15A02 EVQLVESGGGLVQPGGSLRLSCAASGSSYSMGWFRQAPGKEREFVATISWSGG (SEQ ID NO: (D68A,V78I)- NYVANSVKGRFTISRDNAKNTVYLQMNSLRPEDTAVYYCAAGTQFSFSYRQYD 20) HIS6 HIS6 YWGQGT LVTVS SAAAHHHHHH
[0180] P01900037 15A02 EVQLVESGGGLVQPGGSLRLSCAASGSSYSMGWFRQAPGKEREFVATISWSGG (SEQ ID NO: (N69D,V78I)- NYVDDSVKGRFT I S RDNAKNTVYLQMNS LRPEDTAVYYCAAGTQFSFSYRQYD 21) HIS6 HIS6 YWGQGT LVTVS SAAAHHHHHH
[0181] 15A02
[0182] P01900038 (V67Y,D68A,N EVQLVESGGGLVQPGGSLRLSCAASGSSYSMGWFRQAPGKEREFVATISWSGG (SEQ ID NO: 69D,V78I)- NYYADSVKGRFT I S RDNAKNTVYLQMNS LRPEDTAVYYCAAGTQFSFSYRQYD
[0183]
[0184] 22) HIS6 HIS6 YWGQGT LVTVS SAAAHHHHHH
[0185] Table 3: Amino acid sequences of variant VHHs binding Gal10. SEQ ID NO: 12, 16 and 17 are variant sequences of VHH antibody 13C03. SEQ ID NO: 13 and 18 are variant sequences of VHH antibody 13C06 and SEQ ID NO: 15, 19, 20, 21 and 22 are variant sequences of VHH antibody 15A02.BaLa / PETTRACER / 880
[0186] In a next step the sequence optimized (SO) variants were compared.
[0187] 5. Binding affinity of the sequence optimized variants
[0188] The impact on the mutations in the SO variants on Gal10 binding was assessed in binding ELISA. Human Gal10 protein was coated onto Maxisorp F 96-well plates (Thermo Fischer Scientific, Cat 442404) (250 ng in 0.05 mL / well) for 2 days at 4°C. Subsequently plates were blocked with Superblock for 2 hours at room temperature. Plates were dried, and stored at-20°C until use. Plates were washed with washing buffer (PBS, 0.05% Tween20, 0.1% BSA). Dilution series of SO variants in sample buffer (1:10 diluted blocking buffer in PBS) were incubated for 2 hours at room temperature. Plates were washed 3 times with washing buffer after each incubation step with an automated plate washer. The binding of VHHs was detected by a 1 hour incubation at 25 °C with THE anti-HIS antibody (A00186, Genscript, Piscataway, NJ, USA), followed by a 0.5 hour incubation at 4°C with Goat anti-mouse IgG HRP (Thermofisher scientific, Cat nr). Binding was detected by addition of TMB substrate (Chemlab, Cat nr CL07), and the reaction was stopped with 0.5M H2SO4 (Chemlab) after 15 minutes at room temperature. The absorbance at OD450nm and OD620nm were read in a Victor plate reader. Graphpad prism was used for curve fitting using 4PL non-linear regression, to calculate EC50 values.
[0189] Results are summarized in Table 4. Variant P01900032 shows a loss in binding affinity to Gal10, with 21 -fold change in EC50 compared to basic variant P0190007, suggesting that mutation of residue D66Y is not tolerated. All other variants show binding affinities comparable to their respective basic variant.BaLa / PETTRACER / 880
[0190]
[0191]
[0192] Table 4: summary of the binding affinity results and the biochemical and biophysical parameters of the optimized variants. ID numbers and SEQ ID NO: correspond with Table 3.BaLa / PETTRACER / 880
[0193] 6. Biochemical and biophysical stability of the sequence optimized variants
[0194] The impact of the mutations on thermal stability was assessed by determination of the melting (Tm) temperatures of the different SO variants by measuring protein unfolding with Sypro orange. Binding of Sypro Orange (Invitrogen; Waltham, MA, USA) to hydrophobic patches was monitored upon temperature-induced unfolding in an Uncle or QuantStudio5 qPCR (Thermo Fisher; Waltham, MA, USA) instrument. 10 pl (Uncle) or20pl (qPCR) of sample was tested at 1 mg / ml (Uncle) or 0.2mg / ml (qPCR) and a 10x Sypro Orange concentration. A linear temperature ramp was initiated from 25 to 95°C (Uncle) or 25 to 99°C (qPCR) at a rate of 0.5°C / min (Uncle) or 0.05°C / min (qPCR). A pre-run incubation for 180 s (Uncle) or 15 s (qPCR) was applied and excitation occurred at 473nm (Uncle) or 520±nm (qPCR). Area under curve of fluorescence emission spectra (Uncle) or 558 ±11 nm (qPCR) signals were plotted against temperature. Infliction point at which the protein is half-unfolded, Tm, was derived from the local minimum / maximum of the first derivative curve.
[0195] A summary of the results are shown in Table 4 and in Figure 5. Except for one, all SO variants show improved thermal stability as indicated by higher Tm values compared to their respective basic variants, P01900007 (13C03), P01900008 (13C06), and P01900010 (15A02). Only P01900035 has a drop in Tm (66°C) compared to P01900010 (71°C).
[0196] In addition, we assessed potential aggregation and precipitation of SO variants when formulated at higher concentrations, and after repetitive freeze-thaw cycles. Each variant was concentrated > 3 mg / mL in PBS using ultracentrifugation filters with molecular weight cutoff of 3 kDa. The occurrence of precipitates was measured at A340nm, and protein recovery was calculated by protein concentration determination at A280 (Lunatic). Results are shown in Table 4. The 15A02 variants P01900010 and P01900037 show relatively low recovery after up-concentration (66% and 71%), while other variants show acceptable behaviour.
[0197] Dynamic light scattering (DLS) was carried out to measure the visible and sub-visible particle formation propensities of variants. Samples were analyzed with an without one week incubation at 40 °C to assess the impact of temperature stress. Here, 9 pL of sample at 1 mg / mL was applied to the sample cuvette at 25 °C, run in duplicates, with for each ten times acquisitions obtained over a timeframe of 10 seconds (n=20). Correlation functions of the amplitude were determined with and without a cutoff set at amplitude of 0.14, and used to calculate the single hydrodynamic diameter (in nm) using Prism Graphpad. From the dotplot the median, average and standard deviation values per sample were determined.
[0198] Results of the median hydrodynamic diameter before and after 1 week at 40°C are listed in T able 4. Basic variant of 15A02, P01900010, seems sensitive to temperature stress, as one week incubation at 40°C results in increased hydrodynamic diameter (from 3.7 to 11 nm). Variants P0190034, 36, 37 and 38 are not affected by temperature stress. The basic variant of 13C03,BaLa / PETTRACER / 880
[0199] P01900007, has higher sensitivity to temperature stress (increase from 4.4 to 14.6 nm), which is not observed in its variants P01900032 and P01900033.
[0200] 7.PET / CT imaging experiments with lead VHHs binding galectin-10
[0201] 7.1 Conjugation of lead Gal10 VHHs
[0202] Variant P019000033 (SEQ ID NO: 17) was selected as the preferred seguence optimization variant of 13C03 for testing in PET imaging studies, and variant P01900038 (SEQ ID NO: 22) was selected as the preferred seguence optimization variant of 15A02 - herein further designated as the leads. Since 15A02 is not a protein A binder, it was decided to pursue with His-tagged VHHs for imaging studies.
[0203] Both VHHs were derivatized to a octadentate bifunctional chelate desferrioxamine (DFO*NCS), as chelator of choice for89Zr immuno-positron emission tomography (PET), essentially according to the protocol of Vugts et al. (2017) Eur. J. Nucl. Med. Mol. Imaging 44(2):286). In vivo grade purity batches were generated of the 2 seguence optimized variants, P01900033 and P01900038. Nanobodies were purified from periplasmatic fraction using IMAC purification and extensive washing with empigen detergent for endotoxin removal, and a preparative size exclusion chromatography step to obtain > 95% purity. The leads were concentrated to 2 mg / mL for conjugation to the [89Zr] chelator DFO*NCS. The leads were buffer-exchanged into metal-free NaHCO3buffer (50 mM, pH 8.5, Fagron) using Amicon ultracentrifugation with a 10 kDa MWCO membrane (UFC801024, Sigma-Aldrich). A 10-fold molar excess of DFO*-NCS (ABX Chemicals) was added from a 5 mg / mL DFO*-NCS solution in DMSO. The reaction was incubated overnight at 4°C, followed by purification via size-exclusion HPLC (Superdex75 Increase 10 / 300 column, Cytiva). Fractions were collected to obtain a sufficiently pure sample of DFO*-Nb constructs. The final sample concentration was determined using a Nanodrop One C (Thermo Fisher).
[0204] For guality control, cold zirconium labeling was carried out and thereto 10 nmol of DFO*-VHH was added to a 1.5 mL low-bind Eppendorf tube (VWR) containing 500 pL HEPES buffer (0.5 M, pH 7.2, Sigma-Aldrich), 100 pL of 5 mM ZrCI4(Acros Organics) in 1 M oxalic acid (Sigma-Aldrich), and 45 pL Na2CO3solution (2 M, Fluka). The volume was adjusted to 1 mL with 0.9% (m / v) NaCI saline. The mixture was incubated at 37°C for 1 hour with shaking at 400 RPM, and purified using Amicon ultracentrifugation with a 10 kDa MWCO membrane at 4°C for four cycles towards D-PBS.
[0205] The degree of incorporation of DFO* was assessed by mass spectrometry analysis. In the DFO-P01900033 a fraction of 67% contained one DFO moiety, whereas for DFO-P01900038 a 8% fraction with one DFO group incorporated. The Gal 10 binding affinities of the DFO*VHHBaLa / PETTRACER / 880
[0206] conjugates and reference compounds was determined with BLI (as described in example 2). Results of DFO*Nb conjugates are shown in table 5.
[0207] Gal10 In vitro autoradiography ELISA Lung slices Average % Average % % ID STDEV % Blocked STDEV
[0208] bound bound Blocked89Zr-DFO*-P01900033 32.1 3.9 1.89 0.07
[0209] 89Zr- DFO*-P01900033 + 75.9 30.8
[0210] 7.7 3.6 1.31 0.11
[0211] 75 pM unlabeled
[0212] 89Zr- DFO*-P01900038 25.3 1.5 0.80 0.00
[0213] 89Zr- DFO*-P01900038 + 100.1 15.3 0.0 3.9 1.89 0.07
[0214]
[0215] 75 pM unlabeled
[0216] Table 5: Target binding of89Zr-DFO*- P01900033 and89Zr-DFO*- P01900038
[0217] For radiolabelling, Zirconium-89 was sourced from Cyclotron VII Radiopharmaceuticals and Radionuclides (Amsterdam, Netherlands). Radioactivity measurements were performed using an ionization chamber-based activity meter (Capintec Dose Calibrator CRC-55tR). For [89Zr]Zr-DFO*-P01900033, 40 MBq of Zirconium-89 in 1 M oxalic acid was mixed with 500 pL HEPES buffer (0.5 M, pH 7.2), 45 pL Na2CO3solution (2 M), 72.03 pL oxalic acid (1 M, Sigma-Aldrich), and 5 nmol of DFO-P01900033*. The volume was adjusted to 1 mL with 0.9% (m / v) NaCI solution, and incubated at 37°C for 1 hour with shaking at 400 RPM. For [89Zr]Zr-DF0*-P01900038, 75 MBq of Zirconium-89 in 1 M oxalic acid was added in 500 pL HEPES buffer (0.5 M, pH 7.2), 45 pL Na2CO3solution (2 M), 47.55 pL oxalic acid (1 M), and 10 nmol of DFO-P01900038*. The volume was adjusted to 1 mL with 0.9% (m / v) NaCI solution, and incubated at 37°C for 1.5 hours with shaking at 400 RPM. The radiolabeled mixtures were purified using Amicon ultracentrifugation with a 10 kDa MWCO membrane (Sigma-Aldrich) for 10 minutes at 4°C. To block nonspecific binding, 10 nmol of unlabeled P01900033 was added to [89Zr]Zr-DF0-P01900033*, and 5 nmol of unlabeled P01900038 was added to [89Zr]Zr-DFO-P01900038*. Centrifugation was repeated for four cycles, each time adding 1 mL of formulation buffer, which consisted of 5 mg / mL ascorbic acid (Fluka) in 1X D-PBS (pH 7.4).
[0218] The radiochemical purity and Nb concentration in the final tracer solutions were assessed using Radio-SEC-HPLC after radiolabeling and prior to in vivo injection. Both DFO-P01900033 and DFO-P01900038 where radiolabeled successfully, yielding [89Zr]Zr-DFO-P01900033 and [89Zr]Zr-DFO-P01900038 in high radiochemical purity after purification (>99%). [89Zr]Zr-DF0-P01900033* had an activity of 20.7 MBq / 16.56 nmol / mL, and [89Zr]Zr-DFO-P01900038* 21.3 MBq / 19.1 nmol / mL.BaLa / PETTRACER / 880
[0219] 7.2-Specific target binding by in vitro radiography
[0220] To confirm target binding of the radiolabeled conjugates, the final formulation of [89Zr]Zr-DF0-P01900033* and [89Zr]Zr-DFO-P01900038* was analysed for binding to Gal10 in ELISA, as well as to mucus-embedded CLCs by in vitro autoradiography.
[0221] Untagged Gal 10 was coated in maxisorp ELISA plates (250 ng / well), blocked with synblock blocking buffer. Plates were washes three times and subseguently incubated with [89Zr]Zr-DFO*-P01900033 (3.5x1 O'13mol / 50 pL) or [89Zr]Zr-DFO*-P01900038 (9x1 O’13mol / 50 pL) per well (n=4). The same conditions were tested with an excess of the corresponding unlabeled VHH (75 uM), to confirm specific binding. After 1 hour incubation, plates were washed and radioactivity was guantified.
[0222] Binding of [89Zr]Zr-DFO-P01900033* and [89Zr]Zr-DFG-P01900038*to CLCs was assessed by in vitro radiography on lung slices containing CLCs embedded in surrogate mucus plugs. A hydrogel instilled mouse model was used for the PET / CT imaging study, and to generate lung slices for in vitro autoradiography. Briefly, peptide hydrogel 1% (w / v) was prepared by addition of 10 mg CM63 peptide in 1 mL sterile PBS (Gibco # 14190094) and seguential vortexing and centrifugation (Heremans et al, 2020). Hydrogels were stored rest overnight at room temperature. FITC-labelled Gal 10 crystals were added in a 1 / 10 dilution to peptide gels to a final concentration of 1.43 mg / mL. In total 100 pg Gal10 crystals was administered in 70 pl of 1% peptide hydrogel via the intratracheal route to 7 week old male C57BL / 6 mice, anesthetized lightly with isoflurane. Three days following instillation, mice were sacrificed with Nembutal (KELA, BE-V102891) at a concentration of 100 mg / kg via intraperitoneal injection. The lung lobes were collected and immediately snap frozen to generate cryocoupes. For in vitro autoradiography, the same amount (50 ul) of final tracer [89Zr]Zr-DFO-P01900033* and [89Zr]Zr-DFO-P01900038* was used as for the ELISA.
[0223] Results are shown in Figure 6, both [89Zr]Zr-DFO*-P01900033 and [89Zr]Zr-DFO*-P01900038 bind specifically towards CLCs in mouse lungs slices. [89Zr]Zr-DFO-P01900033 seems to show higher uptake than [89Zr]Zr-DFO-P01900038 in in vitro autoradiography.
[0224] 7.3-In vivo PET / CT imaging
[0225] The in vivo targeting ability of two Gal10 radioconjugates binding to Gal10 / Charcot-Leyden Crystals were assessed in a mouse model by PET / CT imaging. To this end an hydrogel-instilled mouse model was used, in which CLCs were embedded in surrogate mucus plugs. In total 100 pg fluorescent Gal 10 crystals were administered in 70 pl of 1% peptide hydrogel via the intratracheal route to 7 week old male C57BL / 6 mice, anesthetized lightly with isoflurane. Three days following instillation, mice were used for immune pPET / CT imaging, in each group 4 mice. In parallel, 3 mice per group were used for analysis of radiometabolites in serum, 10 minutes after radiotracer injection.BaLa / PETTRACER / 880
[0226] For89Zr-DFO-P01900033 the single dose injected activity was 2.07±0.09 MBq / mouse (mass 1.66±0.07 nmol / mouse). For89Zr-DFO-P01900038, the injected activity was 2.2±0.14 MBq / mouse (mass 1.98±0.13 nmol / mouse) for PET. Dynamic PET / CT imaging was done over a timeframe of 2 hours, acquisition was done in a p-cube PET scanner (Molecubes, Ghent, Belgium) and X-cube CT scanner (Molecubes). After imaging, mice were sacrified for ex vivo biodistribution of tissues, and processing of the lungs for immunohistochemistry analysis.
[0227] Results of the ex vivo biodistribution at endpoint (2 hours) are shown in Figure 7. Uptake of radiotracer in tissues is depicted as % injected dose per gram tissue, and as Standardized Uptake Value (SUV): ((SUV; tissue activity concentration (MBq / g) / [injected activity (MBq) / body weight (g)])). pPET / CT imaging results are shown in Figure 8. In panel 8A, the maximum intensity projection PET images of all 4 mice per group at timepoint 110-120 minutes are depicted, in figure 8B detailed picture on 1 mouse from each group. Figure 9 depicts the time-activity curves for each compound in the lungs from 0-120 minutes ((SUV g / mL; tissue activity concentration (MBq / mL) / [injected activity (MBq) / body weight (g)])).
[0228] Animals in both groups show widespread heterogeneous uptake and retention of tracer in the lung. [89Zr]Zr-DFO-P01900033 seems to show higher lung uptake than [89Zr]Zr-DFO-P01900038, as analyzed by pPET / CT and ex vivo biodistribution. Radio metabolite analysis in serum 10 minutes post injection indicates intact radiotracer percentage of average 81% for [89Zr]Zr-DFO-P01900033, and 88% for [89Zr]Zr-DFO-P01900038. The high kidney uptake observed is consistent with the pharmacokinetic profile and short serum-half-life of VHHs. Ex vivo autoradiography was done on lung slices from all animals injected with [89Zr]Zr-DFO-P01900033 (Figure 10) and [89Zr]Zr-DFO-P01900038 (Figure 11), indicating a punctuate staining for both groups. Together these data indicate that radioconjugates of P01900033 and P01900038 both bind well to Gal10-containing CLCs in vivo following intravenous injection.
[0229] Materials and methods
[0230] Gal10 binding ELISA
[0231] Human Gal10 protein was coated onto Maxisorp F 96-well plates (Thermo Fischer Scientific, Cat 442404) at 5 pg / mL in 0.1 mL / well for 2 days at 4°C. Subsequently plates were blocked with Superblock for 2 hours at room temperature. Plates were dried, and stored at -20°C until use. Alternatively, Maxisorp 96-wells plates were coated with N-terminal His-tagged Gal10, that is unable to form CLCs, in 0.1 mL at 1 ug / mL at 4°C overnight. Subsequently plates were blocked with commercial Superblock buffer for 2 hours at room temperature.
[0232] Dilution series of purified VHHs in sample buffer (1:10 diluted blocking buffer in PBS) were incubated for 60 min at 25°C. Plates were washed 3 times with washing buffer (PBS, 0.05% Tween20, 0.1% BSA) after each incubation step with an automated plate washer. The bindingBaLa / PETTRACER / 880
[0233] of VHHs was detected by a 60-min incubation at 25 °C with an anti-HIS antibody (A00186, Genscript, Piscataway, NJ, USA), diluted 1:500, followed by a 30-min incubation at 4°C Goat anti-mouse IgG HRP (Thermofisher scientific, Cat nr), diluted 1:1000. Binding was detected by addition of TMB substrate (Chemlab, Cat nr CL07), and the reaction was stopped with 0.5M H2SO4 (Chemlab) after 15 minutes at RT. The absorbance at OD450nm and OD620nm were read in a Victor plate reader. Graphpad prism was used for curve fitting using 4PL non-linear regression.
[0234] Protein thermal stability measurements
[0235] Two techniques were used to determine the melting temperatures (Tm) of proteins.
[0236] Binding of Sypro Orange (Invitrogen; Waltham, MA, USA) to hydrophobic patches was monitored upon temperature-induced unfolding in an Uncle or QuantStudio5 qPCR (Thermo Fisher; Waltham, MA, USA) instrument. 10pl (Uncle) or 20pl (qPCR) of sample was tested at 0.75mg / ml (Uncle) or 0.2mg / ml (qPCR) and a 10x Sypro Orange concentration. A linear temperature ramp was initiated from 25 to 95°C (Uncle) or 25 to 99°C (qPCR) at a rate of 0.5°C / min (Uncle) or 0.05°C / min (qPCR). A pre-run incubation for 180 s (Uncle) or 15 s (qPCR) was applied and excitation occurred at 473nm (Uncle) or 520±nm (qPCR). Area under curve of fluorescence emission spectra (Uncle) or 558 ±11 nm (qPCR) signals were plotted against temperature. Infliction point at which the protein is half-unfolded = Tm was derived from the local minimum / maximum of the first derivative curve.
[0237] Intrinsic tryptophan-fluorescence was monitored upon temperature-induced protein unfolding in an Uncle instrument (Unchained Labs; Pleasanton, CA, USA). Here, 10 pL of sample at 1 mg / mL was applied to the sample cuvette, and a linear temperature ramp was initiated from 25 to 95 °C ata rate of 0.5 °C / min, with a pre-run incubation for 180 s. The barycentric mean (BCM) and static light scattering (SLS at 266 nm and 473 nm) signals were plotted against temperature in order to obtain Tm and aggregation onset temperatures (Tagg), respectively.
[0238] Protein surface hydrophobicity measurements
[0239] The relative surface hydrophobicity of proteins in their folded state (Munch and Bertolotti, 2010) was assessed as follows. Sypro Orange (Invitrogen; Waltham, MA, USA) binding to hydrophobic patches at 25°C was measured in an Uncle instrument (Unchained Labs; Pleasanton, CA, USA).
[0240] 10 pL of sample at 1 mg / ml was tested in presence of a 10x Sypro Orange concentration. Prerun incubation of 180s was followed by a linear ramp between 25 and 26°C at a rate of 0.1 °C / min. Fluorescent signals were detected between 250 and 727nm, measurement at 25°C was reported.BaLa / PETTRACER / 880
[0241] Aggregation assays
[0242] Analytical size-exclusion chromatography (aSEC) was carried out by applying 20 pL of a 1 mg / mL protein sample to an Agilent SEC3 (4.6mmx300mm) (Mw 500-150,000) column on an Agilent HPLC system (Agilent; Santa Clara, CA, USA). Samples were run in PBS at a flow rate of 0.4mL / min. The outlet of the column was coupled to a UV detector. Retention time, recovery and percentage pre-peak are derived from UV280 measurements.
[0243] Seguence listing
[0244] SEQ ID NO: 1 - 13C03 VHH from WO2019197675 (therein depicted as SEQ ID NO: 263) QVQLVESGGGLVQPGGSLRLSCAASGSIFSISRMGWYRQAPGKQRELVAIIFSDASTDYA DSVKGRFTISRSNAKNTVYLQMNSLKPEDTAVYYCKSVLRAAGYGYFNQYWGQGTQVTVSS
[0245] SEQ ID NO: 2 - 15A02 VHH from WO2019197675 (therein depicted as SEQ ID NO: 266) QVQLVESGGGLVQAGGSLRLSCAASGSSYSMGWFRQAPGKEREFVATISWSGGNYVDNSV KGRFTVSRDNAKNTVYLQMNSLKPEDTAVYYCAAGTQFSFSYRQYDYWGQGTQVTVSS
[0246] SEQ ID NO: 3 - 13C06 VHH from WO2019197675 (therein depicted as SEQ ID NO: 253) QLQLVESGGGLVQAGGSLRLSCAASSSSYSMGWFRQAPGKEREFVATISWSGGFYYDDSV KGRFTVSRDNAKNTVYLQMNSLKPEDTAVYYCAAGTRFSFSYREYHYWGQGTQVTVSS
[0247] SEQ ID NO: 4 - 1D06 VHH from WO2019197675 (therein depicted as SEQ ID NO: 265) QLQLVESGGGLVQPGGSLRLSCAASENSVSTYAMGWFRQAPGKEREFVAAITRAGGNTYN ADSVKGRFTISRDNAENTIYLQMNSLKPEDTAVYSCAAGPRYSTISTMFPYWGQGTQVTVSS
[0248] SEQ ID NO: 5 - 13E09 VHH from WO2019197675 (therein depicted as SEQ ID NO: 259) QVQVQESGGGLVQAGNSLRLSCAASGRTFSSYHMMWFRQAPGKEREFVAAIAWRGGTYCA NSVKGRCTISRDNAKDTVYLQMNSLKPEDTAVYFCAASLRYVFDPSAMDYWGKGTLVTVSS
[0249] SEQ ID NO: 6 until SEQ ID NO: 22 (see table)
[0250] CDR seguences in SEQ ID NO: 17 (lead of 13C03):
[0251] CDR1: GSIFSISR (SEQ ID NO: 23)
[0252] CDR2: IIFSDAST (SEQ ID NO: 24)
[0253] CDR3: KSVLRAAGYGYFNQY (SEQ ID NO: 25)
[0254] CDR seguences in SEQ ID NO: 22 (lead of 15A02)
[0255] CDR1: GSSYS (SEQ ID NO: 26)
[0256] CDR2: ISWSGGN (SEQ ID NO: 27)
[0257] CDR3: AAGTQFSFSYRQYDY (SEQ ID NO: 28)
Claims
BaLa / PETTRACER / 880Claims1. An immunoglobulin variable domain (IVD) that specifically binds to the crystalline form of galectin 10 said IVD comprises a CDR3 sequence consisting of an amino acid sequence with maximally two amino acids different from SEQ ID No. 25 or 28 and / or wherein said IVD comprises a CDR2 sequence consisting of an amino acid sequence with maximally two amino acids different from SEQ ID No. 24 or 27 and / or wherein said IVD comprises a CDR1 sequence consisting of an amino acid sequence maximally two amino acids different from SEQ ID no. 23 or 26.
2. The IVD according to claim 1, wherein the CDR3 sequence is as depicted in SEQ ID No. 25 or 28 and / or wherein the CDR2 sequence is depicted in SEQ ID No. 24 or 27 and / or wherein the CDR1 sequence is depicted in SEQ ID No. 23 or 26.
3. The IVD according to claims 1 or 2 comprising an amino acid sequence with at least 90% identity over the full length of said sequence to SEQ ID No. 17 or 22.
4. The IVD according to claims 1 , 2 or 3 wherein said IVD is an immunoglobulin single variable domain (ISVD).
5. The IVD according to claims 1 , 2 or 3 wherein said IVD is an immunoglobulin single variable domain (ISVD).
6. The ISVD according to claim 4 comprising an amino acid sequence depicted in the sequences SEQ ID No. 17 or 22.
7. A labelled-lVD conjugate comprising:a. an IVD according to any of claims 1 to 5, andb. a detection label conjugated to the IVD, wherein the detection label is a radionuclide tracer, a fluorophore or a nanoparticle.
8. The labelled-lVD conjugate of claim 7 wherein the radionuclide tracer is conjugated to the IVD with a bifunctional chelator, prosthetic group, or linker, and wherein the bifunctional chelator, prosthetic group, or linker is attached to the IVD and to the radionuclide tracer.
9. The labelled-lVD conjugate of claim 7 wherein the bifunctional chelator comprises a chelator selected from desferrioxamine (DFO*NCS), 1,4,7-Triazacyclononane (TACN); 1,4,7,10- Tetraazacyclododecane (Cyclen); 1,4,7,10-Tetraazacyclododecane-1,7-diacetic acid (D02A); 1,4,7,10-Tetraazacyclododecane-1,4,7-triacetic acid trisodium salt (D03A); 1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA); 1,4,7,10- Tetraazacyclododecane-1,4,7,10-tetra(methylene phosphonic acid) (DOTP); 1,4,8,11- Tetraazacyclotetradecane-1, 4, 8, ll-tetraacetic acid (TETA); 2,2',2”,2”’-(l,4,8,ll- tetraazacyclotetradecane-1,4,8,1 1-tetrayl)tetraacetamide (TETAM); 1,4,7,10- Tetrakis(carbamoylmethyl)-1,4,7,10-tetraazacyclododecane (DOTAM); 2,2',2”-(1 ,4,7, 10- tetraazacyclododecane-1 ,4,7-triyl)triacetamide (D03AM); 1 ,8-Diamino-3,6, 10, 13, 16, 19- 33BaLa / PETTRACER / 880hexaazabicyclo[6,6,6]-eicosane (DiAmSar); 1,4, 8,1 1-Tetraazabicyclo[6.6.2]hexadecane (CB-Cyclam); 2,2'-(1,4,8, 1 1-tetraazabicyclo[6.6.2]hexadecane-4,1 1 -diyl)diacetic acid (CB- TE2A); 1,4,7-Triazacyclononane-1,4,7-triacetic acid (NOTA); 1,4,7-Triazacyclononane- 1,4,7 -tri(methylene phosphonic acid) (NOTP); 3-(((4,7- bis((hydroxy(hydroxymethyl)phosphoryl)methyl)-1,4,7-triazonan-l- yl)methyl)(hydroxy)phosphoryl)propanoic acid (NOPO); 2,2',2”-(1,4,7-triazacyclononane- 1,4,7-triyl)triacetamide (NOTAM) ; 2, 2', 2”, 2”’ - ((((carboxymethyl)azanediyl)bis(ethane-2,l- diyl))bis(azanetriyl))tetraacetic acid (DTPA); 3,6,9, 15-Tetraazabicyclo[9.3.1]pentadeca- l(15),11,13-triene-3,6,9-triacetic acid (PCTA); 2,2',2”,2”’-(1,4,7,10-tetraazacyclotridecane- 1.4.7.10-tetrayl)tetraacetic acid (TRITA); 2,2',2”,2”’-(1,4,7,10-tetraazacyclotridecane- 1.4.7.10-tetrayl)tetraacetamide (TRITAM); 2,2',2”-(1,4,7,10-tetraazacyclotridecane-1,4,7- triyl)triacetamide (TRITRAM); and 3,3',3”-(((1,4,7-triazonane-1,4,7- triyl)tris(methylene))tris(hydroxyphosphoryl))tripropanoic acid (TRAP); or a combination of any two or more thereof.
10. The labelled-lVD conjugate of claims 7 to 8 wherein the radionuclide tracer is selected from:11C,13N,150,18F,44Sc,45Ti,52Mn,64Cu,68Ga,44Sc,76Br,82Rb,86Y,89Zr,90Y,99mTc,111In,124l,131l,43K,52Fe,57Co,67Cu,67Ga,77Br,81Rb,81mKr,87mSr,89Zr,113mln,123l,125l,127Cs ,129Cs,132l,177Lu,186Re,197Hg,203Pb.206Bi,82Sr,188Re,60Cu,61Cu,62Cu,225Ac,225Ra, and a combination of any two or more thereof.
11. A nucleic acid molecule encoding the IVD according to any one of claims 1 to 5.
12. A vector comprising the nucleic acid molecule according to claim 10.
13. A host cell comprising the nucleic acid molecule according to claim 11 or the vector according to claim 12.34
